Legis Daily

Medicare IVIG Access Enhancement Act

USA116th CongressHR-2905| House 
| Updated: 5/23/2019
Earl Blumenauer

Earl Blumenauer

Democratic Representative

Oregon

Cosponsors (24)
Dwight Evans (Democratic)Adrian Smith (Republican)John Garamendi (Democratic)Robin L. Kelly (Democratic)Max Rose (Democratic)Terri A. Sewell (Democratic)Susan A. Davis (Democratic)Wm. Lacy Clay (Democratic)Kenny Marchant (Republican)Christopher H. Smith (Republican)G. K. Butterfield (Democratic)Elaine G. Luria (Democratic)Mike Kelly (Republican)Doris O. Matsui (Democratic)David E. Price (Democratic)Jerrold Nadler (Democratic)James P. McGovern (Democratic)Ron Kind (Democratic)Julia Brownley (Democratic)Debbie Lesko (Republican)Brian K. Fitzpatrick (Republican)Susan W. Brooks (Republican)George Holding (Republican)Jenniffer González-Colón (Republican)

Ways and Means Committee, Energy Subcommittee, Health Subcommittee, Energy and Commerce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Medicare IVIG Access Enhancement Act This bill requires the Centers for Medicare & Medicaid Services to establish a three-year demonstration project to evaluate the benefits of providing Medicare coverage and payment for items and services needed for the in-home administration of intravenous immune globulin to treat chronic inflammatory demyelinating polyneuropathy or multifocal motor neuropathy. Beneficiary participation shall be voluntary.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
May 22, 2019
Introduced in House
May 22, 2019
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
May 22, 2019
Sponsor introductory remarks on measure. (CR E657)
May 23, 2019
Referred to the Subcommittee on Energy.
May 23, 2019
Referred to the Subcommittee on Health.
  • May 22, 2019
    Introduced in House
  • May 22, 2019
    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  • May 22, 2019
    Sponsor introductory remarks on measure. (CR E657)
  • May 23, 2019
    Referred to the Subcommittee on Energy.
  • May 23, 2019
    Referred to the Subcommittee on Health.

Health

Congressional oversightDrug therapyGovernment studies and investigationsHome and outpatient careMedicareNeurological disorders

Medicare IVIG Access Enhancement Act

USA116th CongressHR-2905| House 
| Updated: 5/23/2019
Medicare IVIG Access Enhancement Act This bill requires the Centers for Medicare & Medicaid Services to establish a three-year demonstration project to evaluate the benefits of providing Medicare coverage and payment for items and services needed for the in-home administration of intravenous immune globulin to treat chronic inflammatory demyelinating polyneuropathy or multifocal motor neuropathy. Beneficiary participation shall be voluntary.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
May 22, 2019
Introduced in House
May 22, 2019
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
May 22, 2019
Sponsor introductory remarks on measure. (CR E657)
May 23, 2019
Referred to the Subcommittee on Energy.
May 23, 2019
Referred to the Subcommittee on Health.
  • May 22, 2019
    Introduced in House
  • May 22, 2019
    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  • May 22, 2019
    Sponsor introductory remarks on measure. (CR E657)
  • May 23, 2019
    Referred to the Subcommittee on Energy.
  • May 23, 2019
    Referred to the Subcommittee on Health.
Earl Blumenauer

Earl Blumenauer

Democratic Representative

Oregon

Cosponsors (24)
Dwight Evans (Democratic)Adrian Smith (Republican)John Garamendi (Democratic)Robin L. Kelly (Democratic)Max Rose (Democratic)Terri A. Sewell (Democratic)Susan A. Davis (Democratic)Wm. Lacy Clay (Democratic)Kenny Marchant (Republican)Christopher H. Smith (Republican)G. K. Butterfield (Democratic)Elaine G. Luria (Democratic)Mike Kelly (Republican)Doris O. Matsui (Democratic)David E. Price (Democratic)Jerrold Nadler (Democratic)James P. McGovern (Democratic)Ron Kind (Democratic)Julia Brownley (Democratic)Debbie Lesko (Republican)Brian K. Fitzpatrick (Republican)Susan W. Brooks (Republican)George Holding (Republican)Jenniffer González-Colón (Republican)

Ways and Means Committee, Energy Subcommittee, Health Subcommittee, Energy and Commerce Committee

Health

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Congressional oversightDrug therapyGovernment studies and investigationsHome and outpatient careMedicareNeurological disorders